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The prediction of pituitary tumour behaviour, in terms of response
to treatment from which can be derived optimal management
strategies, is a challenge that has been approached using several
different means. This paper assesses the role of measurements of
cell proliferation and angiogenesis in predicting tumour behaviour.
Although metastasis is extremely rare, local recurrence and inva-
sion are important problems and we have investigated whether
factors of importance in epithelial cancers are also relevant in
these tumours.
There are currently no reliable histological or molecular
markers that predict pituitary tumour behaviour and response to
treatment. Assessment of cell proliferation by measuring the
proportion of cells that have entered the cell cycle has been
suggested as a potential means of predicting tumour behaviour
(Thapar et al, 1996; Turner and Wass 1999). The MIB-1 labelling
index (LI) (proportion of cells in the cell cycle) of hormonally
active tumours has been shown to be higher than in endocrinolog-
ically inactive adenomas (Thapar et al, 1996) although the reason
for this difference is unclear.
Bcl-2, the protein product of the bcl-2 proto-oncogene, inhibits
programmed cell death (apoptosis) and gives cells that over-
express this protein a survival advantage (Hockenbery, 1992).
There has been one previous small study in the pituitary showing
that 30% of tumours expressed bcl-2 and suggesting that this may
play a role in pituitary tumour pathogenesis through regulation of
apoptosis (Wang et al, 1996). Bcl-2 has also been shown to have
an inhibitory effect on cell growth (Knowlton et al, 1998).
In many tumour types, angiogenesis (measured as tumour
microvessel density (MVD)) has been shown to be correlated with
different aspects of tumour behaviour including development of
metastasis (Weidner et al, 1991), poor prognosis (Weidner et al,
1992; Weidner, 1996), lower survival (Bochner et al, 1995; Maeda
et al, 1995) and recurrence (Gasparini et al, 1994; Frank et al,
1995). MVD has been measured by counting vessels identified by
positive immunostaining with antibodies to different vascular
endothelial markers. Different antibodies demonstrate different
sensitivities for the detection of endothelium. Factor eight-related
antigen (F8) stains large vessels but does not label smaller
microvessels (Mukai et al, 1980), CD31 stains microvessels but
antigen loss can make this unreliable in paraffin-embedded tissue
and ulex europaeus agglutinin I (UEAI) stains all microvessels,
but also stains the Golgi in some neoplastic cells (Holthofer et al,
1982; Witt and Klessen, 1987; Vermeulen et al, 1996).
Our previous work has demonstrated reduced angiogenesis in
pituitary adenomas compared with the normal anterior pituitary
(Turner et al, submitted). The aim of this study was to assess the
value of the three phenomena: angiogenesis, cell proliferative
capacity and anti-apoptotic protein expression in predicting
tumour behaviour, as well as to investigate the relationship
between tumour angiogenesis, cell proliferation and cell survival
capacity.
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Summary The prediction of pituitary tumour behaviour, in terms of response to treatment from which can be derived optimal management
strategies, is a challenge that has been approached using several different means. Angiogenesis in other tumour types has been shown to be
correlated with poor response to treatment and tumour recurrence. The aim of this paper is to assess the role of measurements of cell
proliferation and angiogenesis in predicting pituitary tumour behaviour. The proliferative capacity of the tumour was assessed using the Ki-67
labelling index (LI) while bcl-2 expression was used to assess anti-apoptotic pathways. The microvessel density (MVD) was assessed using
antibodies to CD31 and factor VIII-related antigen, and with biotinylated ulex europaeus agglutinin I. There was no difference between Ki-67
LI and MVD of functionless tumours that recurred and those that did not, but bcl-2 expression was significantly lower in tumours that
subsequently regrew. Macroprolactinomas had significantly higher LI than microprolactinomas and than all other tumours. Cell proliferation
and angiogenesis were not related, showing that both processes are under different control mechanisms in pituitary tumours. In contrast there
was a positive relationship between markers of angiogenesis and bcl-2 expression in prolactinomas, GH-secreting tumours and non-recurrent
functionless tumours with higher levels of bcl-2 expression being found in the more vascular tumours. These findings may suggest that
angiogenesis is related to the ability of tumour cells to survive rather than their proliferative activity. © 2000 Cancer Research Campaign
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Specimen collection
A total of 160 surgically removed pituitary adenomas were inves-
tigated. There were 46 GH-secreting tumours (28 macroade-
nomas and 18 microadenomas), seven microprolactinomas,
22 macroprolactinomas, 18 ACTH-secreting tumours (Cushing’s
disease) and 53 non-functioning pituitary adenomas (28
gonadotrophin positive and 14 negative), 11 of which subse-
quently recurred. In addition, 14 specimens of recurrent function-
less tumours removed following second or third operations for
regrowth were studied. There were paired samples of tumour from
first and second operations in ten cases. Two of the recurrent
tumours had been exposed to pituitary irradiation between the first
and second operations. All the tissue was fixed in 4% buffered
formalin, dehydrated and embedded in paraffin. Histological
examination and immunohistochemistry for anterior pituitary
hormones had been performed previously and together with the
clinical, biological and radiological data were used to fully charac-
terize each tumour type.
Immunohistochemistry
The streptavidin–biotin peroxidase complex technique was used
for CD31, F8, Ki-67 and bcl-2 and the alkaline phosphatase/anti-
alkaline phosphatase (APAAP) method was used for UEAI.
Four-micrometre sections were mounted on aptes (3-amino-
propyl triethoxy silane; Sigma)-coated slides, dewaxed and rehy-
drated. Endogenous peroxidase activity was blocked using 3%
hydrogen peroxide where applicable. Non-specific primary anti-
body binding was blocked using fetal calf serum at a dilution of
1:20 for CD31, UEAI and bcl-2. The details of pretreatment,
primary and secondary antibodies and colour reactions are shown
in Table 1. The slides were lightly counterstained with haema-
toxylin.
Assessment of vascular density and quantification of
Ki-67 and bcl-2 labelling
All quantification was performed by a single observer without
knowledge of tumour type or size.
Quantification of the Ki-67-labelled cells was performed using
an image analysis system (VIDAS 21) (Nagy et al, 1997). Tumour
cell nuclear staining was recorded as the percentage of positive
cells (LI).
Slides stained with bcl-2 were quantified after examination of
the whole tumour section at ´10, using a semiquantitative method
on a scale from 0 to 3 (none, low density staining, moderate
density staining, dense staining respectively) at ´20 and ´40.
The Chalkley point technique was used to measure micro-
vascular density (Fox et al, 1995). The most vascular area of the
tumour was identified at low power as the hot spot. A 25-point
Chalkley graticule was orientated so that the maximum number of
randomly positioned points seen through the eyepiece at higher
power were on or within areas of highlighted vessels. The mean of
the counts for the three most vascular areas was recorded. An
overall subjective semiquantitative grading system was also used
(1 and 2 – low and low moderate, and 3 and 4 – moderate and high
vascular density). The counts and grades were made by a single
observer, and 20% checked by a second blinded observer. We have
previously demonstrated good interobserver reliability (100%
concordance for grading into low and high vascular density) and
intraobserver reliability k value of 0.6 representing substantial
agreement (Landis and Koch, 1977) for vascular counts.
Statistical analysis
The Statgraphics software package was used. The analysis of
variance (ANOVA) test was used for categorical data analysis
and regression analysis for comparison of continuous variables.
Differences between groups were regarded as significant if
P < 0.05.
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Table 1 Antibodies used
Primary antibodya Pretreatment Secondary antibodyb Colour development
CD31 1/20 (DAKO) 0.1% trypsin, followed by Antimouse 1/200 (Insight Horseradish peroxidase
microwavec Biotech) streptavidin 1/400 (Dako)
and DABd
F8 EPOS (DAKO) 0.1% trypsin None DABd
UEAI 1/100 (Vector) None APAAP complex (Vector) Fast red (20 minutes)
Ki-67 EPOS (DAKO) Microwavec None DABd
bcl-2 1/20 Microwavec Antimouse horseradish DABd
peroxidase labelled polymer
(Envision, Dako)
aPrimary antibodies all applied for 60 min. bSecondary antibody applied for 30 min. cMicrowave in sodium citrate pH 6. dDAB, metal-enhanced diaminobenzidine
(Pierce and Warriner).
Table 2 Vascular density and labelling index (Ki-67) of recurrent and non-recurrent functionless tumours
CD31M CD31G F8M F8G UEAIM UEAIG Ki67 LI bcl2 grade
Non-recurrent tumours 5.4 (0.2) [34] 2.7 (0.1) [34] 5.1 (0.2) [43] 2.3 (0.1) [43] 7.4 (0.4) [42] 2.9 (0.1) [42] 4.3 (0.53) [40] 1.1 (0.1) [40]
Recurrent first presentation 5.5 (1.0) [0.3] 2.4 (0.2) [11] 5.4 (0.5) [8] 2.2 (0.3) [8] 7.7 (0.8) [9] 3.1 (0.2) [9] 4.1 (1.0) [11] 0.2 (0.2) [11]
Second presentation 5.4 (0.3) [14] 2.4 (0.2) [14] 5.9 (0.4) [13] 2.6 (0.2) [14] 7.4 (0.7) [12] 2.9 (0.2) [12] 3.3 (1.0) [12] 0.4 (0.2) [14]
Mean (SE) [n]. M represents mean Chalkley count, and G represents overall semiquantitative grade.RESULTS
Ki-67 LI
There was no difference in MVD of functionless tumours that
recurred when compared with those that did not (Table 2). Some of
the sections of normal pituitary showed one nucleus staining posi-
tively for Ki-67, but the majority showed no staining. In contrast,
the LI in pituitary adenomas varied between 2.9 and 8.4 depending
on tumour type (Figure 1). The LI with Ki-67 was unrelated to
whether a non-functioning pituitary tumour recurred or not, and
there was no significant difference between the LI of the tumour
when the first presentation of a recurrence was compared with the
second (Table 2). The LI of macroprolactinomas was significantly
higher than the LI of all other tumours P < 0.05 (Figure 1).
Microprolactinomas had the lowest Ki-67 LI.
Relationship between Ki-67 LI and bcl-2 expression or
vascular density
There was no association between Ki-67 LI and vascular density
or bcl-2 expression for any tumour type studied. The relationship
of MVD to tumour type, behaviour and size have been previously
reported (Turner et al, submitted).
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Figure 1 Comparison of Ki-67 labelling indices in different tumour types. LI:
Ki-67 labelling index. Mean values and standard errors. Acro: GH-secreting
tumours; NFA: non-functioning tumours; MacPRL: macroprolactinomas;
MicPRL: microprolactinomas; Cushing’s: ACTH-secreting tumours. n is the
number of cases in each category. The asterisk indicates the tumour type
significantly different (P < 0.05) from all other tumour types
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Figure 2 Comparison of Bcl-2 expression in different tumour types. Mean
values and standard errors. Bcl-2: semiquantitative grading of the extent of
Bcl-2 labelling. Acro: GH-secreting tumours; NFA: non-functioning tumours;
MacPRL: macroprolactinomas; MicPRL: microprolactinomas; Cushing’s:
ACTH-secreting tumours. n is the number of cases in each category. The
asterisk indicates the tumour type significantly different (P < 0.05) from all
other tumour types
Table 3 Tumour type and bcl-2 expression
Tumour type Number (%) – bcl2 positive
NFA (non-recurrent) 31/40 (77.5)
NFA (recurrent)
First presentation 2/11 (18.2)
Second presentation 6/14 (42.9)
Macroprolactinoma 17/22 (77.3)
Microprolactinoma 5/7 (71.4)
GH-secreting tumour 36/46 (78.3)
Micro 12/18 (66.7)
Macro 17/28 (60.7)
ACTH-secreting tumour 9/18 (50)
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Figure 3 Bcl-2 expression in recurrent and non-recurrent functionless
tumours. Bcl-2: semiquantitative grading of the extent of Bcl-2 labelling. Non-
rec: non-recurrent functionless pituitary adenomas; Rec-1: functionless
pituitary adenomas that subsequently recurred – first presentation; Rec-2:
recurrent functionless pituitary adenomas – presentation of recurrence.
Dotted line and asterisk indicate statistically significant difference (P < 0.05)
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Figure 4 Relationship between the vascular density and Bcl-2 expression
in pituitary tumours. Note y-axis is truncated. UEA1: vascular density as
measured by UEA1 staining; Bcl-2: semiquantitative grading of the extent of
Bcl-2 labelling. Dotted lines and asterisks indicate statistically significant
differences (P < 0.05)bcl-2 expression
Normal pituitary did not show positive immunostaining for bcl-2.
However, bcl-2 was expressed by over half of the tumours studied
with the exception of functionless tumours that recurred (Table 3).
bcl-2 grade was significantly higher in GH-secreting tumours
compared to ACTH-secreting tumours, NFA and macroprolactin-
omas. Excluding recurrent functionless tumours, ACTH-secreting
tumours were of a significantly lower bcl-2 grade than all other
tumours (Figure 2). There was no significant difference in bcl-2
grade between microprolactinomas and macroprolactinomas.
The bcl-2 grade was significantly higher in functionless
tumours that did not recur than those that did (Figure 3).
bcl-2 expression and angiogenesis
bcl-2 expression was significantly associated with MVD, with
higher bcl-2 expression found in the more vascular tumours
(Figure 4). Examination of adjacent sections showed that bcl-2
expression was not necessarily associated with vascular hot spots.
DISCUSSION
The lack of association between MVD and functionless tumour
recurrence indicates that angiogenesis is unlikely to be a major
factor in determining which of these tumours regrow. It suggests
that other factors such as the amount of residual tumour remaining
after surgery or perhaps alterations in cell cycle control (Jin et al,
1997) are more important. It is clear that MVD cannot be used to
predict which tumour may subsequently recur and therefore
require prophylactic radiotherapy. In contrast to some studies of
cell proliferation that have suggested that the Ki-67 LI concords
with recurrence after treatment (Knosp et al, 1989; Abe et al,
1997), our data show that the Ki-67 LI as a reflection of tumour
proliferation is not useful to predict subsequent behaviour of
functionless tumours. The definition of recurrent and non-
recurrent tumours may be a confounding factor as pre-emptive
radiotherapy may be given to avoid tumour regrowth and recur-
rence. Inadequate duration of follow-up may inadvertently place a
recurrent tumour in the non-recurrent group and finally much of
what is defined as recurrence may simply be regrowth of a slowly
growing tumour in a location with difficult surgical access.
The Ki-67 LI of macroprolactinomas was significantly higher
than all other tumours, in keeping with the fact that they often
behave more aggressively than other benign pituitary tumours and
often show local invasion. The significant difference between
Ki-67 LI of macroprolactinomas and microprolactinomas is in
support of the data from Delgrange et al (1997) who demonstrated
that microadenomas producing prolactin had a significantly lower
Ki-67 LI than macroadenomas. Our data showed no relationship
between tumour size and LI in any other tumour type, confirming
the findings of other studies (Knosp et al, 1989; Thapar et al, 1996;
Turner and Wass, 1999), and suggesting that other factors such as
cell cycle arrest, duration of the cell cycle or the rate of cell death
are important in determining tumour size.
The lack of an association between Ki-67 LI and MVD in pitu-
itary tumours is not entirely surprising as the LI is simply a
measure of the proportion of cells that have entered the cell cycle
and gives no idea of the speed of progress through the cycle and
therefore tumour growth, which in pituitary adenomas is usually
slow. Our data are in support of work in breast cancer and
colorectal cancer where intratumoural MVD measured using anti-
CD34 and the LI measured using Ki-67 were not related
suggesting that angiogenesis and tumour cell proliferation may be
regulated by different means (Fox et al, 1993; Vartanian and
Weidner, 1994; Vermeulen et al, 1997). In theory, it might be
expected that MVD could limit tumour growth by limiting cell
proliferation although this is clearly not the case in the pituitary. It
has been suggested that the lack of correlation may be because the
MVD is more indicative of the apoptotic rather than the prolifera-
tive fraction of cells (Vermeulen et al, 1997).
In the only previous study looking at bcl-2 expression in pitu-
itary tumours, bcl-2 was demonstrated using immunohistochem-
istry to be present in 30% of tumours but not in functionless
tumours or normal tissue. Our data have shown that bcl-2 expres-
sion is found in over 50% tumours and in particular that 2/3 of the
functionless tumours express bcl-2. The differences between the
two studies may be related to differences in tissue fixation,
numbers of tumours studied, antibodies or immunohistochemistry
technique (Envision). This finding supports the suggestion that
bcl-2 expression may be an early event in pituitary tumorigenesis
leading to indolent tumour growth and cell survival despite slow
rates of cell proliferation as bcl-2 expression is known to inhibit
cell proliferation (Knowlten et al, 1998). It is also consistent with
the fact that apoptosis is an apparently rare event in pituitary
tumours. The positive association between bcl-2 expression and
MVD suggests that the control of angiogenesis and programmed
cell death may be related – perhaps a switch to an angiogenic
phenotype and bcl-2 expression are both early events in pituitary
tumorigenesis or that non-cycling but surviving cells support
angiogenesis. The important pro-angiogenic growth factor,
vascular endothelial growth factor (VEGF), has been shown to be
present in endocrine tissue (Christofori et al, 1995; Fan and Iseki,
1998; Terris et al, 1998) as well as in tumours. It has been
suggested that VEGF may be of particular importance in
endocrine tissue, as it also maintains endothelial permeability
allowing direct access to the bloodstream. It has recently been
demonstrated that VEGF not only stimulates endothelial prolifera-
tion, but also prolongs endothelial cell survival by inducing
expression of bcl-2, suggesting that part of the angiogenic activity
of VEGF may be related to protection of endothelial cells from
apoptosis (Nor et al, 1999).
It is therefore perhaps surprising that bcl-2 expression was
lower in recurrent tumours than non-recurrent. Although bcl-2
expression may protect from apoptosis, it also inhibits cell growth,
and in breast and lung cancer bcl-2 expression is associated with
less aggressive tumour behaviour (Fontanini et al, 1995; Berado
et al, 1998; Charpin et al, 1998). It is therefore likely that a reduc-
tion in bcl-2 expression reflects a change in another pathway that
promotes survival and aggressive behaviour, allowing bcl-2 to be
down-regulated. The relationship between bcl-2 and angiogenesis
has recently been explored by Carmaliet and colleagues who
showed that bcl-2 is regulated by hypoxia. Increased hypoxia
inducible factor-1 (HIF-1a) expression in response to reduced
oxygen tension leads to suppression of bcl-2 along with increased
VEGF and angiogenesis (Carmaliet et al, 1998). The lower expres-
sion of bcl-2 in recurrent tumours may thus be a reflection of
hypoxia-induced increased HIF-1a expression and secondary
suppression of bcl-2 expression. The positive association between
MVD and bcl-2 expression in the other pituitary tumour types is
difficult to reconcile with the above findings but it has been
suggested that the role of HIF-1a in apoptosis may depend on cell
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p53 is a known inhibitor of tumour angiogenesis (Dameron et al,
1994). Further steps in pituitary tumour progression may involve
inactive or mutant p53 expression which inhibits HIF-1-stimulated
transcription (Blagosklonny et al, 1998). It is known that only very
aggressive pituitary tumours express p53 (Thapar et al, 1996b).
A reciprocal relationship between p53 expression and bcl-2 has
been demonstrated in other tumour types, where only very aggres-
sive tumours express p53 (Fontanini et al, 1995).
In conclusion, we have shown that MVD and bcl-2 expression
in pituitary tumours are associated, suggesting that angiogenesis
may be linked to the ability of cells to survive. There was no rela-
tionship between MVD and Ki-67 LI, suggesting that angiogenesis
and proliferation are regulated by different means. We have
demonstrated that neither angiogenesis nor cell proliferation were
predictive of subsequent tumour recurrence but shown that bcl-2
expression was significantly lower in tumours that regrew than
those that did not. Cell proliferation as measured using the Ki-67
LI was significantly higher in macroprolactinomas than other
tumours, in keeping with their known clinical behaviour. It will be
useful to study more recurrent and non-recurrent tumours as well
as some malignant tumours to further investigate the relationship
between bcl-2 expression, p53, hypoxia and MVD.
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